NRx Pharmaceuticals announced that it has entered into an agreement with LS Associates, a division of LifeSci Advisors, pursuant to which LSA will provide certain consulting services to the company, including but not limited to, arranging for the provision of the company’s Interim CFO. In connection with the Agreement, the company appointed Richard Narido to serve as Interim CFO of the company. As Interim CFO, Narido will serve as the company’s principal financial officer and principal accounting officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRXP:
- NRx Pharmaceuticals announces data on in vitro activity of NRX-101
- NRx Pharmaceuticals announces submission of IND application for NRX-101
- NRx Pharmaceuticals to purchase 3M shares of preferred stock at 40c per share
- NRx Pharmaceuticals reports Q2 EPS (12c), consensus (14c)
- NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update